SCHEMBL12424279

SCHEMBL12424279

CCC1CCN(Cc2nc(C)no2)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RBP1 P09455 1/20 0.45
▸ LMNA P02545 3/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HTT P42858 1/20 0.43
▸ RAB9A P51151 5/20 0.43
▸ NPC1 O15118 4/20 0.43
▸ POLB P06746 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ MITF O75030 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15014635 0.84 RAB9A (0.58) RBP1LMNAMAPK1HTTRAB9A
SCHEMBL12384751 0.80 RAB9A (0.42) RBP1LMNAMAPK1HTTRAB9A
SCHEMBL12519914 0.80 RAB9A (0.56) LMNAMAPK1HTTRAB9ANPC1
SCHEMBL8352583 0.78 RAB9A (0.59) LMNAMAPK1HTTRAB9ANPC1
SCHEMBL15014518 0.78 RAB9A (0.49) LMNARAB9ANPC1POLBALDH1A1
SCHEMBL12384487 0.78 POLB (0.45) RBP1LMNARAB9ANPC1POLB
SCHEMBL12424346 0.77 ALDH1A1 (0.36) LMNARAB9ANPC1POLBALDH1A1
SCHEMBL8348678 0.77 SMN1; SMN2 (0.60) LMNAHTTRAB9ANPC1POLB
SCHEMBL16303842 0.76 SMN1; SMN2 (0.42) LMNAMAPK1HTTRAB9ANPC1
SCHEMBL15014608 0.74 RAB9A (0.40) LMNARAB9ANPC1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201593-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2011-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201593-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF CCNY, CCNA1, CCNA2 RBP1 3126/4885LMNA 1043/4885MAPK1 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback